| Roflumilast | Astrazeneca | ||
| 500 mcg;Tablet, Oral |
Less Than $1000 mn
|
||
|
More Than 5
|
More Than 5
|
||
|
Less Than 5
|
None | ||
|
More Than 5
|
More Than 5
|
||
| Indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. | |||
|
Yes
| |||
| Daliresp | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 |
|---|---|---|---|---|---|---|
| ****** | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ***** | ******* | ******* | ******* | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ****** | *** \ *** | *** **, **** | ******* | ******** | ******** ** *** **, **** |
| ******* | *** \ *** | *** **, **** | ******* | ******** | ******** ** *** **, **** |
| ***** | *** \ *** | *** **, **** | ******* | ******** | *** ****** ******* |
| Roflumilast | Astrazeneca | ||
| 250 mcg; Tablet. Oral |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
| None | None | ||
|
More Than 5
|
Less Than 5
|
||
| Roflumilast is used to control and prevent symptoms ( wheezing and shortness of breath) caused by ongoing lung disease ( chronic obstructive pulmonary disease - COPD which includes bronchitis ). | |||
|
Yes
| |||
| Daliresp | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 |
|---|---|---|---|---|---|---|
| *** **** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* |
| ***** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* |
| ***** ****** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| *** **** | *** \ *** | -**- | *** ********* | ******** | ******** ** *** **, **** |
| ***** | ** \ ** | -**- | *** ********* | ******** | *** ****** ******* |
| ***** ****** | ** \ ** | -**- | *** ********* | ******** | ******** ** *** **, **** |
Download ParaIV Report